UroToday22h
ASCO GU 2025: Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to the prostate cancer poster session. Dr. Andrei Gafita ...
UroToday22h
ASCO GU 2025: Recurrence after Radiation Therapy: Evaluation, Management, and Outcomes
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Management of Biochemical ...
UroToday1d
ASCO GU 2025: Management of Biochemical Recurrence After Radiation Therapy for Localized Prostate Cancer with Salvage Surgery
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based ...
UroToday1d
A brief history of urinary catheters
The word “catheter” comes from Greek, meaning “to let or send down.” Catheters were used as early as 3,000 B.C. to relieve painful urinary retention. In those times, many materials were used to form a ...
UroToday1d
ASCO GU 2025: Capturing What You Cannot See: How Can ctDNA Be Used to Improve Clinical Staging for Upper Tract Disease?
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13th and 15th 2025, was host to the Panning for Gold: ...
UroToday1d
ASCO GU 2025: Age-Related Efficacy and Safety of Darolutamide + ADT and Docetaxel in Patients with mHSPC: A Subgroup Analysis of ARASENS
(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Joan Carles discussing a subgroup analysis of ARASENS assessing age-related efficacy and ...
UroToday1d
ASCO GU 2025: Real-World Outcomes of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Jacob Moyer discussing real-world outcomes of nadofaragene firadenovec in BCG-unresponsive ...
UroToday1d
ASCO GU 2025: Potential Impact of ctDNA on Perioperative Management of Muscle-Invasive Bladder Cancer
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Panning for Gold: The Role of ctDNA as a Biomarker for ...
UroToday1d
ASCO GU 2025: Real World Toxicity Profile of Enfortumab Vedotin with or Without Pembrolizumab in Ultra Elderly Urothelial Carcinoma Patients
(UroToday.com) The 2025 GU ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Nataliya Mar discussing real world toxicity profile of enfortumab vedotin with or ...
UroToday1d
ASCO GU 2025: Case-Based Session: Non-Muscle Invasive Bladder Cancer: Exploring Therapies Beyond Bacillus Calmette-Guérin
(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Case-Based Session: Non-Muscle Invasive Bladder Cancer ...
UroToday1d
ASCO GU 2025: Phase 1b/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naive Patients With Advanced Clear Cell RCC
(UroToday.com) The 2025 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu ...
UroToday1d
ASCO GU 2025: Development of a FKSI-23: A New Bespoke Health-Related Quality of Life Questionnaire for the Advanced and Adjuvant Setting in RCC
(UroToday.com) The 2025 GU ASCO annual meeting featured a kidney cancer session and a presentation by Dr. Cristiane Bergerot discussing the development of FKSI-23, a new bespoke health-related quality ...